Table 1.
Summary of studies conducted on development of therapies for Sanfilippo disease (MPS III) and reported during last 3 years (2014–2017)
| MPS III subtype | Models or trials | Therapies investigated in recent years | |||
|---|---|---|---|---|---|
| ERT | SRT | Other small molecules | Gene therapy | ||
| MPS IIIA | Cellular models | X | X | X | |
| Animal models | X | X | |||
| Clinical trials | X | X | X | ||
| MPS IIIB | Cellular models | X | X | X | |
| Animal models | X | X | X | ||
| Clinical trials | X | X | |||
| MPS IIIC | Cellular models | X | X | ||
| Animal models | |||||
| Clinical trials | X | ||||
| MPS IIID | Cellular models | ||||
| Animal models | X | ||||
| Clinical trials | |||||
The availability of reports on particular kinds of therapies and models are marked by X
Abbreviations: MPS mucopolysaccharidosis, ERT enzyme replacement therapy, SRT substrate reduction therapy